The Study of the Protective Effects of Fargesin on Experimental Ischemia-Reperfusion Injury of Liver in Male Rats

Reperfusion following ischemia can lead to metabolic and structural damage to the liver. Fargesin, known for its anti-inflammatory properties, holds potential applications in the development of drugs targeting inflammatory disorders. Most recent studies on fargesin have focused on its anti-inflammatory effects. This study aimed to evaluate the effects of fargesin on liver function, as well as its antioxidant and inflammatory status, following the induction of ischemia-reperfusion injury in the liver of rats. For this purpose, 40 male Wistar rats were randomly divided into four groups of 10: (1) Sham group: rats without any surgical intervention, (2) Surgical control group: rats subjected to surgery without ischemia-reperfusion, (3) Ischemia-reperfusion group: rats exposed to ischemia followed by 45 minutes of reperfusion, and (4) Ischemia-reperfusion with fargesin treatment group: rats that received fargesin at a dose of 50 mg/kg P.O via gavage for 12 weeks post-ischemia. Blood and liver tissue samples were collected, and the animals were sacrificed. Levels of serum alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase were measured. In the liver tissue homogenates, levels of malondialdehyde and the activities of superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase were assessed. Histopathological examination of liver tissue was performed using light microscopy. In group 4, fargesin significantly (p < 0.05) reduced elevated levels of liver damage marker enzymes, decreased lipid peroxidation, and restored diminished antioxidant levels in the liver. Additionally, histopathological changes in the livers of fargesin-treated rats were significantly ameliorated. The results suggest that fargesin, with its anti-inflammatory properties, exhibits protective effects against ischemia-reperfusion-induced liver injury and could be a potential therapeutic agent for managing ischemia-reperfusion-related liver damage.